Antipsychotic Effects of Oxytocin
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01621737|
Recruitment Status : Terminated (Break in funding)
First Posted : June 18, 2012
Results First Posted : November 19, 2019
Last Update Posted : November 19, 2019
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: Oxytocin Drug: Placebo||Not Applicable|
This is two-site clinical study taking place at UCSD and UCI. Approximately 71 patients at each site will be randomly assigned to either intranasal oxytocin or vehicle placebo at this site.
The total duration for each individual subject will be 6 weeks on study medication (placebo or oxytocin).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||42 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Antipsychotic Effects of Oxytocin|
|Actual Study Start Date :||June 2011|
|Actual Primary Completion Date :||December 2018|
|Actual Study Completion Date :||December 2018|
Experimental: Oxytocin: Low Dose
42 IU BID for the six weeks
42 IU BID for six weeks
Experimental: Oxytocin: High Dose
84 IU BID for six weeks
84 IU BID for six weeks
|Placebo Comparator: Placebo||
- Change in Total Score in the Positive and Negative Syndrome Scale (PANSS)From Baseline to Endpoint [ Time Frame: 6 weeks ]The three subscales of the PANSS include the Positive scale (7 items), the Negative scale (7 items), and the General Psychopathology scale (16 items). The total PANSS score is the sum of all 30 items of which each item is scored on a 1-7 rating system (7 indicating the worst symptoms). The items on the PANSS focus on symptoms that are common in patients with psychotic disorders and include hallucinations, delusions and disorganization as well as mood disturbances.
- Global Assessment of Functioning (GAF) [ Time Frame: 6 weeks ]The GAF considers psychological, social, and occupational functioning on a hypothetical continuum of mental health illness. Scores on the GAF range from 1 (extremely severe) to 100 (superior functioning).
- Clinical Global Impression-Severity of Illness (CGI-S) [ Time Frame: 6 weeks ]The CGI-S is used to evaluate changes in overall severity of illness. Scores range from 1 (not at all) to 7 (among the most extremely ill).
- Clinical Global Impression-Global Improvement (CGI-I) [ Time Frame: 6 weeks ]The CGI-I is a global assessment to evaluate the subject's improvement or worsening from baseline. Scores on the CGI-I scale range from 1 (very much improved) to 7 (very much worse).
- Computerized Multiphasic Interactive Neurocognitive DualDisplayTM System (CMINDS®) [ Time Frame: 6 weeks ]The CMINDS ® consists of "construct-equivalent computerized versions of the neurocognitive assessment instruments constituting the MATRICS™ Consensus Cognitive Battery (MCCB™).
- Mayer-Salovey-Caruso Emotional Intelligence Test: Managing Emotions (MSCEIT™ ME) [ Time Frame: 6 weeks ]The MSCEIT™ ME is a multiple choice test that asses how individuals manage their emotions.
- Calgary Depression Scale for Schizophrenia (CDSS) [ Time Frame: 6 weeks ]The CDSS is a ten item diagnostic questionnaire intended to assess the severity of depression symptoms experienced by a given patient.
- Hamilton-Anxiety Scale (HAM-A) [ Time Frame: 6 weeks ]The HAM-A is a clinician administered scale for the evaluation of anxiety symptoms. It consists of 14 items of which each item is scored 0 (not present) to 4 (very severe).
- Paranoid Thoughts Scale (PTS) [ Time Frame: 6 weeks ]The PTS is a self-rated scale to assess current paranoia symptoms. The PTS consists of 32 items that the subject rates from 1 (not at all) to 5 (totally).
- Treatment Satisfaction Questionnaire for Medication (TSQM) [ Time Frame: 6 weeks ]The TSMQ is a brief questionnaire asking patients about how satisfied they were with the ease, timing, etc. of the study medication giving a good indication of adherence
- Childhood Trauma Questionnaire (CTQ) [ Time Frame: 6 weeks ]The CTQ is a validated measure of adverse early experiences characterized on a measure of Anxiety Sensitivity Index and retrospective childhood maltreatment. A 5-point frequency of occurrence scale is utilized: (1) never true, (2) rarely true, (3) sometimes true, (4) often true, and (5) very often true. Each sub-scale score ranges from 5 (no history of abuse or neglect) to 25 (very extreme history of abuse and neglect).
- Experience Close Relationships (ECR) [ Time Frame: 6 weeks ]The ECR is a self-rated questionnaire designed to assess individual differences with respect to attachment-related anxiety (i.e., the extent to which people are insecure vs. secure about the extent to which their partner's availability and responsiveness) and attachment-related avoidance (i.e., the extent to which people are uncomfortable being close to others vs. secure depending on others) .
- Arizona Sexual Experience Scale (ASEX) [ Time Frame: 6 weeks ]The ASEX is a self-rated scale to assess sexual functioning. The ASEX consists of 5 items that the subject will rate from 1 ("extremely strong", "easily", or "satisfying") to 6 ("absent" or "never") based on how he/she feels at the time.
- Social Phobia Inventory (SPIN) [ Time Frame: 6 weeks ]The SPIN is a patient self-report scale that measures the degree of social phobia in a variety of different social situations.
- Penn Emotion Recognition Test (ER-40) [ Time Frame: 6 weeks ]The ER-40 is a computerized emotion discrimination test presenting 40 color photographs of evoked happy, sad, anger, fear and neutral expressions balanced for poser gender and ethnicity.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01621737
|United States, California|
|University of California, Irvine|
|Irvine, California, United States, 92037|
|University of California, San Diego|
|San Diego, California, United States, 92103|
|Principal Investigator:||David Feifel, MD, Ph.D||UCSD|
|Principal Investigator:||Steven Potkin, MD||UCI|